Asset Details
Do you wish to reserve the book?
Arthur Caplan
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Arthur Caplan
Do you wish to request the book?
Arthur Caplan
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Arthur Caplan
2016
Overview
Arthur Caplan, a medical ethicist at the New York University School of Medicine, discusses how to fairly distribute experimental drugs outside of clinical trials.
Last year, the FDA received 1,262 requests from drug companies, on behalf of desperate patients, to use unapproved drugs outside of clinical trial programmes. The number of 'compassionate use' requests has risen by nearly 25% since 2010, with no sign of abating. Yet, while companies carry most of the onus of deciding which cases to support and which to deny, they typically make their decisions on an ad hoc basis. Social media campaigns and personal connections can sway the outcomes. Arthur Caplan, a medical ethicist at New York University School of Medicine, believes that a fairer decision-making process is needed. He told
Asher Mullard
about a pilot project that he ran with Johnson & Johnson's pharmaceutical company Janssen to equitably and transparently distribute an experimental drug outside of its clinical trial programme.
Publisher
Nature Publishing Group UK,Nature Publishing Group
